#

+91-9811715635

  • #
  • #
  • #
#

Global Healthcare CMO Market (2018-2022 Edition)

Publish Date:Apr 2018
No. of Pages:63

Format : Adobe Reader (PDF) Instant delivery

US$ 800.00

Scope of the Report

This report named “Global Healthcare CMO Market (2018-2022 Edition)”, analysis the growth and sizing of global healthcare CMO market and its segments. This report provides the analysis of global healthcare CMO market by value and by segment.

The analysis of global medical device CMO market is done by value, by players and by cost structure and analysis of global pharmaceutical CMO is done by value and by segments. The global pharmaceutical CMO market by segments is analyzed in detail by providing analysis of each of its segment.

This report includes the analysis of global active pharmaceutical ingredient CMO market by value and analysis of finished dosage formulation CMO market by value, by revenue structure, by geographical approach and by dosage formulation.

This report also provides the analysis of global pharmaceutical CDMO market. This analysis includes the global pharmaceutical CDMO market by value, by players and by geography. The regional analysis of global pharmaceutical CDMO market is also done in this report. The regions included are United States of America, Europe, China and India.

This report also includes the growth drivers, market trends and challenges faced by global healthcare CMO market. Company profiling of major players of healthcare CMO industry is also done in this report. The companies included are Catalent Pharma Solution, Recipharm, Aurobindo Pharma Ltd. and Boehringher Ingelheim. Business overview, financial overview and business strategy for each company is provided.

Company Coverage

Catalent Pharma Solution
Recipharm
Aurobindo Pharma Ltd.
Boehringher Ingelheim
Regional Coverage

The US
Europe
India
China

Executive Summary

Contract manufacturing is a type of outsourcing in which a firm contacts with a third party (contract manufacturing organization) for the manufacturing of components of its product or whole of its product. A contract manufacturing organization (CMO) undertakes the production of product(s) under the brand name of another firm.

A big or a mid-sized firm opt for a CMO mainly for two reasons, either it wants to shift (or reduce) its cost and focus to its core activities, or the manufacturing of its products require special or expert handling.

CMOs provide independent manufacturing services in healthcare sector also. Healthcare CMOs can be segmented into pharmaceutical CMOs and medical device CMOs. After the discovery of chemical formula of a new drug, the pharmaceutical CMOs are given the task of manufacturing it into a whole product, so that the pharmaceutical companies are able to sell it into the market under their brand name. Services offered by pharmaceutical CMOs can be divided into two main activities: primary manufacturing (Active Pharmaceutical Ingredients) and secondary manufacturing (Finished Dosage Formulation). Contract manufacturing for medical devices is one of the fastest growing segments of the medical device industry, as companies are in the race to bring new devices to the market.

From last few years, many pharmaceutical CMOs have included development part into their activities, apart from manufacturing of drugs and they are called contract development & manufacturing organizations (CDMOs). The market for pharmaceutical CMOs and CDMOs can neither be taken as same, nor be taken as completely distinct from each other. Also, these two markets cannot be combined together, as it will exaggerate the global pharmaceutical CMO market.

The global healthcare CMO market has recorded a continuous growth since last few years and is expected to follow the same trend in coming years. The main driving factors for this growth are rise in global pharmaceutical industry, increased need for outsourcing, increased approvals and outsourcing of NMEs, innovations and increased regulatory pressure on quality. Yet there are some challenges, which healthcare CMO industry faces, such as fragmented nature of market, less preference for outsourcing of profitable and biological drugs by big pharmaceutical companies.

1. Executive Summary

2. Introduction

2.1 Contract Manufacturing: An Overview

2.1.1 Healthcare CMOs 
2.1.2 Healthcare CMOs Market Segments
2.1.3 Pharmaceutical CMOs
Active Pharmaceutical Ingredients (API)
Finished Dosage Formulations (FDF)
2.1.4 Medical CMOs

2.2 Pharmaceutical Outsourcing: An Overview

2.2.1 Pharmaceutical Outsourcing Market Segments

2.3 Pharmaceutical CMOs v/s CDMOs 

3. Global Market Analysis

3.1 Global Healthcare CMO Market: An Analysis 

3.1.1 Global Healthcare CMO Market by Value 
3.1.2 Global Healthcare CMO Market by Segments (Medical Device CMO and Pharmaceutical CMO)

3.2 Global Medical Device CMO Market: An Analysis 

3.2.1 Global Medical Device CMO Market by Value 

3.3 Global Pharmaceutical CMO Market: An Analysis 

3.3.1 Global Pharmaceutical CMO Market by Value 
3.3.2 Global Pharmaceutical CMO Market by Region (US, European Union, China, India, Japan, Brazil, Russia and South Korea)
3.3.3 Global Pharmaceutical CMO Market by Segments (API, Finished Dosage Formulation and Other Services)
3.3.4 Global Active Pharmaceutical Ingredient CMO Market by Value
3.3.5 Global Finished Dosage Formulation CMO Market by Value
3.3.6 Global Other Pharmaceutical Services CMO Market by Value

3.4 Global Pharmaceutical CDMO Market: An Analysis 

3.4.1 Global Pharmaceutical CDMO Market by Value
3.4.2 Global Pharmaceutical CDMO Market by Region (US, Europe, India, and China)

4. Regional Analysis

4.1 The US Pharmaceutical CDMO Market: An Analysis 
4.1.1 The US Pharmaceutical CDMO Market by Value

4.2 Europe Pharmaceutical CDMO Market: An Analysis 
4.2.1 Europe Pharmaceutical CDMO Market by Value

4.3 India Pharmaceutical CDMO Market: An Analysis 
4.3.1 India Pharmaceutical CDMO Market by Value

4.4 China Pharmaceutical CDMO Market: An Analysis 
4.4.1 China Pharmaceutical CDMO Market by Value

5. Competitive Landscape

5.1 Global Healthcare CMO Market Players Financial Comparison 

6. Company Profile

6.1 Catalent Pharma Solutions Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy

6.2 Recipharm
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy

6.3 Aurobindo Pharma Limited 
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy

6.4 Boehringer Ingelheim
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy
Figure 1: Healthcare CMOs Market Segments
Figure 2: Pharmaceutical Outsourcing Market Segments
Figure 3: Value Chain of a Drug
Figure 4: Global Healthcare CMO Market by Value; 2012-2017 (US$ Billion)
Figure 5: Global Healthcare CMO Market by Value; 2018-2022 (US$ Billion)
Figure 6: Global Healthcare CMO Market by Segments; 2017 (Percentage, %) (Medical Device CMO and Pharmaceutical CMO)
Figure 7: Global Medical Device CMO Market by Value; 2012-2017 (US$ Billion)
Figure 8: Global Medical Device CMO Market by Value; 2018-2022 (US$ Billion)
Figure 9: Global Pharmaceutical CMO Market by Value; 2012-2016 (US$ Billion)
Figure 10: Global Pharmaceutical CMO Market by Value; 2018-2022 (US$ Billion)
Figure 11: Global Pharmaceutical CMO Market by Region; 2017 (Percentage, %) (US, European Union, China, India, Japan, Brazil, Russia and South Korea)
Figure 12: Global Pharmaceutical CMO Market by Segments; 2017 (Percentage, %) (API, Finished Dosage Formulation and Other Services)
Figure 13: Global Active Pharmaceutical Ingredient CMO Market by Value; 2018-2022 (US$ Billion)
Figure 14: Global Finished Dosage Formulation CMO Market by Value; 2018-2022 (US$ Billion)
Figure 15: Global Other Pharmaceutical Services CMO Market by Value; 2018-2022 (US$ Billion)
Figure 16: Global Pharmaceutical CDMO Market by Value; 2012-2017 (US$ Billion
Figure 17: Global Pharmaceutical CDMO Market by Value; 2018-2022 (US$ Billion)
Figure 18: Global Pharmaceutical CDMO Market by Region; 2017 (Percentage, %) (US, Europe, India, and China)
Figure 19: The US Pharmaceutical CDMO Market by Value; 2012-2016 (US$ Billion)
Figure 20: The US Pharmaceutical CDMO Market by Value; 2017-2021 (US$ Billion)
Figure 21: Europe Pharmaceutical CDMO Market by Value; 2012-2016 (US$ Billion)
Figure 22: Europe Pharmaceutical CDMO Market by Value; 2017-2021 (US$ Billion)
Figure 23: India Pharmaceutical CDMO Market by Value; 2012-2016 (US$ Billion)
Figure 24: India Pharmaceutical CDMO Market by Value; 2017-2021 (US$ Billion)
Figure 25: China Pharmaceutical CDMO Market by Value; 2012-2016 (US$ Billion)
Figure 26: China Pharmaceutical CDMO Market by Value; 2017-2021 (US$ Billion)
Figure 27: Catalent Revenue; 2013-2017 (US$ Billion)
Figure 28: Catalent Revenue by Segments; 20162017 (Percentage, %)
Figure 29: Recipharm Net Sales; 2013-2017 (US$ Million)
Figure 30: Recipharm Net Sales by Segments; 2017 (Percentage, %)
Figure 31: Recipharm Net Sales by Region; 2017 (Percentage, %)
Figure 32: Aurobindo Revenues; 2013-2017 (US$ Billion)
Figure 33: Aurobindo Revenue by Segments; 2017 (Percentage, %)
Figure 34: Boehringher Ingelheim Net Sales; 2012-2016 (US$ Billion)
Figure 35: Boehringher Ingelheim Net Sales by Geography; 2016 (Percentage, %)
Figure 36: Boehringher Ingelheim Net Sales by Business; 2016 (Percentage, %)
Table 1: Global Healthcare CMO Market Players Financial Comparison; 2016-2017